nisoldipine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
calcium channel blockers, nifedipine derivatives 1942 63675-72-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • BAY k-5552
  • nisoldipine
  • nisoldipin
  • zadipina
A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.
  • Molecular weight: 388.42
  • Formula: C20H24N2O6
  • CLOGP: 4.58
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 1
  • TPSA: 107.77
  • ALOGS: -4.83
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.25 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 5 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 5.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 15 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 11 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 2, 1995 FDA SHIONOGI INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intestinal angioedema 26.61 26.41 5 711 584 46684762

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC C08CA07 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
Dihydropyridine derivatives
FDA CS M0006414 Dihydropyridines
FDA MoA N0000000069 Calcium Channel Antagonists
FDA EPC N0000175421 Dihydropyridine Calcium Channel Blocker
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002121 Calcium Channel Blockers
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:35554 cardiovascular drugs
CHEBI has role CHEBI:35620 vasodilator
CHEBI has role CHEBI:35674 antihypertensive
CHEBI has role CHEBI:38215 calcium channel blockers
CHEBI has role CHEBI:50427 platelet aggregation inhibitors
FDA PE N0000178477 Decreased Blood Pressure

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Hepatic failure contraindication 59927004

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.37 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-dependent L-type calcium channel subunit alpha-1D Ion channel BLOCKER UNKNOWN CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel GATING INHIBITOR IC50 7.10 IUPHAR CHEMBL
Adenosine receptor A2a GPCR Ki 5.64 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 5.40 DRUG MATRIX
Cytochrome P450 1A2 Enzyme IC50 6 DRUG MATRIX
Voltage-dependent T-type calcium channel subunit alpha-1H Ion channel Ki 5.34 WOMBAT-PK
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 4.59 CHEMBL
Voltage-dependent P/Q-type calcium channel subunit alpha-1A Ion channel WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 4.64 WOMBAT-PK
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel GATING INHIBITOR IC50 8 IUPHAR
Voltage-dependent L-type calcium channel subunit alpha-1D Ion channel GATING INHIBITOR IC50 7 IUPHAR

External reference:

IDSource
4020942 VUID
N0000148422 NUI
D00618 KEGG_DRUG
4020942 VANDF
C0028116 UMLSCUI
CHEBI:7577 CHEBI
CHEMBL1726 ChEMBL_ID
D015737 MESH_DESCRIPTOR_UI
DB00401 DRUGBANK_ID
2524 IUPHAR_LIGAND_ID
4753 INN_ID
4I8HAB65SZ UNII
4499 PUBCHEM_CID
7435 RXNORM
147682 MMSL
5178 MMSL
d03825 MMSL
004175 NDDF
108524004 SNOMEDCT_US
386861009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nisoldipine HUMAN PRESCRIPTION DRUG LABEL 1 0378-2096 TABLET, FILM COATED, EXTENDED RELEASE 8.50 mg ORAL ANDA 16 sections
Nisoldipine HUMAN PRESCRIPTION DRUG LABEL 1 0378-2097 TABLET, FILM COATED, EXTENDED RELEASE 17 mg ORAL ANDA 16 sections
Nisoldipine HUMAN PRESCRIPTION DRUG LABEL 1 0378-2098 TABLET, FILM COATED, EXTENDED RELEASE 25.50 mg ORAL ANDA 16 sections
Nisoldipine HUMAN PRESCRIPTION DRUG LABEL 1 0378-2099 TABLET, FILM COATED, EXTENDED RELEASE 34 mg ORAL ANDA 16 sections
Nisoldipine HUMAN PRESCRIPTION DRUG LABEL 1 0378-2222 TABLET, FILM COATED, EXTENDED RELEASE 20 mg ORAL ANDA 25 sections
Nisoldipine HUMAN PRESCRIPTION DRUG LABEL 1 0378-2223 TABLET, FILM COATED, EXTENDED RELEASE 30 mg ORAL ANDA 25 sections
Nisoldipine HUMAN PRESCRIPTION DRUG LABEL 1 0378-2224 TABLET, FILM COATED, EXTENDED RELEASE 40 mg ORAL ANDA 25 sections
Nisoldipine HUMAN PRESCRIPTION DRUG LABEL 1 0677-1978 TABLET, FILM COATED, EXTENDED RELEASE 8.50 mg ORAL NDA authorized generic 27 sections
Nisoldipine HUMAN PRESCRIPTION DRUG LABEL 1 0677-1979 TABLET, FILM COATED, EXTENDED RELEASE 17 mg ORAL NDA authorized generic 27 sections
Nisoldipine HUMAN PRESCRIPTION DRUG LABEL 1 0677-1980 TABLET, FILM COATED, EXTENDED RELEASE 25.50 mg ORAL NDA authorized generic 27 sections
Nisoldipine HUMAN PRESCRIPTION DRUG LABEL 1 0677-1981 TABLET, FILM COATED, EXTENDED RELEASE 34 mg ORAL NDA authorized generic 27 sections
Nisoldipine HUMAN PRESCRIPTION DRUG LABEL 1 54868-5931 TABLET, FILM COATED, EXTENDED RELEASE 40 mg ORAL ANDA 26 sections
SULAR HUMAN PRESCRIPTION DRUG LABEL 1 54868-5993 TABLET, FILM COATED, EXTENDED RELEASE 25.50 mg ORAL NDA 26 sections
Nisoldipine HUMAN PRESCRIPTION DRUG LABEL 1 66993-472 TABLET, FILM COATED, EXTENDED RELEASE 8.50 mg ORAL NDA AUTHORIZED GENERIC 26 sections
Nisoldipine HUMAN PRESCRIPTION DRUG LABEL 1 66993-473 TABLET, FILM COATED, EXTENDED RELEASE 17 mg ORAL NDA AUTHORIZED GENERIC 26 sections
Nisoldipine HUMAN PRESCRIPTION DRUG LABEL 1 66993-475 TABLET, FILM COATED, EXTENDED RELEASE 34 mg ORAL NDA AUTHORIZED GENERIC 26 sections
Sular HUMAN PRESCRIPTION DRUG LABEL 1 70515-500 TABLET, FILM COATED, EXTENDED RELEASE 8.50 mg ORAL NDA 25 sections
Sular HUMAN PRESCRIPTION DRUG LABEL 1 70515-501 TABLET, FILM COATED, EXTENDED RELEASE 17 mg ORAL NDA 25 sections
Sular HUMAN PRESCRIPTION DRUG LABEL 1 70515-503 TABLET, FILM COATED, EXTENDED RELEASE 34 mg ORAL NDA 25 sections